Publications

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types.

Authors: H-C Chen, N Mueller, K Stott, C Kapeni, E Rivers, CM Sauer, F Beke, SJ Wals...

Research group: Brenton Group, de la Roche Group, Mair Group

E-pub date: 1 Nov 2024

Journal name: EMBO Mol Med

Deuterium MRI of serine metabolism in mouse models of glioblastoma.

Authors: F Hesse, J Low, J Cao, F Bulat, F Kreis, AJ Wright, KM Brindle

Research group:

E-pub date: 1 Nov 2024

Journal name: Magn Reson Med

Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage.

Authors: A Moumen, P Masterson, MJ O'Connor, SP Jackson

Research group: Jackson Group

E-pub date: 31 Oct 2024

Journal name: Cell

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.

Authors: BH Nelson, P Hamilton, MT Phung, K Milne, B Harris, S Thornton, D Stevens, ...

Research group: Brenton Group

E-pub date: 29 Oct 2024

Journal name: J Clin Invest

Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus

Authors: R Wray, H Paverd, I Machado, J Barbieri, F Easita, AR Edwards, FA Gallagher...

Research group: de la Roche Group

E-pub date: 28 Oct 2024

Journal name:

P01.01.A CHARACTERIZATION OF GLIOBLASTOMA’S MIGRATION HETEROGENEITY THROUGH A PATIENT-DERIVED 3D MODEL

Authors: A Pujol-Castiblanque, T Savin, AE Markaki, R Mair

Research group: Mair Group

E-pub date: 17 Oct 2024

Journal name: Neuro-Oncology

CELL-INTRINSIC METABOLIC PHENOTYPES IDENTIfiED IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY IMAGING OF 13C-LABELED GLUCOSE METABOLISM

Authors: A Tsyben, A Dannhorn, G Hamm, DL Couturier, M Briggs, R Mair, K Brindle

Research group:

E-pub date: 15 Oct 2024

Journal name: Neuro-Oncology

POSTOPERATIVE VISUAL fiELD DEfiCITS ARE NOT ASSOCIATED WITH REDUCTION IN QUALITY OF LIFE IN GLIOBLASTOMA PATIENTS

Authors: Y Wan, Y Li, R Sinha, S Jain, R Mair, R Morris, A Joannides, T Santarius, S...

Research group: Mair Group

E-pub date: 15 Oct 2024

Journal name: Neuro-Oncology

Filters

Research Groups

Core Facilities

Start date

End date

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types.

Deuterium MRI of serine metabolism in mouse models of glioblastoma.

Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage.

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.

Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus

P01.01.A CHARACTERIZATION OF GLIOBLASTOMA’S MIGRATION HETEROGENEITY THROUGH A PATIENT-DERIVED 3D MODEL

CELL-INTRINSIC METABOLIC PHENOTYPES IDENTIfiED IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY IMAGING OF 13C-LABELED GLUCOSE METABOLISM

POSTOPERATIVE VISUAL fiELD DEfiCITS ARE NOT ASSOCIATED WITH REDUCTION IN QUALITY OF LIFE IN GLIOBLASTOMA PATIENTS

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Publisher Correction: Novel immunotherapeutics against LGR5 to target multiple cancer types.

Deuterium MRI of serine metabolism in mouse models of glioblastoma.

Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage.

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer.

Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus

P01.01.A CHARACTERIZATION OF GLIOBLASTOMA’S MIGRATION HETEROGENEITY THROUGH A PATIENT-DERIVED 3D MODEL

CELL-INTRINSIC METABOLIC PHENOTYPES IDENTIfiED IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY IMAGING OF 13C-LABELED GLUCOSE METABOLISM

POSTOPERATIVE VISUAL fiELD DEfiCITS ARE NOT ASSOCIATED WITH REDUCTION IN QUALITY OF LIFE IN GLIOBLASTOMA PATIENTS